Elevance Health, Inc. (NYSE:ELV – Get Free Report)’s share price crossed below its 50-day moving average during trading on Wednesday. The stock has a 50-day moving average of $416.91 and traded as low as $400.12. Elevance Health shares last traded at $401.3980, with a volume of 1,907,972 shares changing hands.
Analysts Set New Price Targets
ELV has been the subject of several research reports. Wall Street Zen raised shares of Elevance Health from a “hold” rating to a “buy” rating in a research report on Saturday, November 7th. Guggenheim raised their target price on shares of Elevance Health from $460.00 to $485.00 and gave the stock a “buy” rating in a research report on Thursday, October 22nd. TD Cowen lifted their price target on shares of Elevance Health from $465.00 to $495.00 and gave the company a “buy” rating in a research note on Friday, October 23rd. Royal Bank Of Canada lifted their price target on shares of Elevance Health from $424.00 to $455.00 and gave the company a “sector perform” rating in a research note on Thursday, October 22nd. Finally, Robert W. Baird boosted their price target on Elevance Health from $393.00 to $406.00 and gave the company a “neutral” rating in a report on Thursday, October 22nd. Sixteen analysts have rated the stock with a Buy rating and seven have given a Hold rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $458.91.
Check Out Our Latest Stock Report on ELV
Elevance Health Stock Performance
The stock has a market cap of $86.73 billion, a PE ratio of 17.12, a price-to-earnings-growth ratio of 2.07 and a beta of 0.63. The company has a quick ratio of 1.47, a current ratio of 1.47 and a debt-to-equity ratio of 0.68. The firm has a 50 day moving average price of $416.91 and a 200 day moving average price of $376.44.
Elevance Health (NYSE:ELV – Get Free Report) last released its quarterly earnings data on Wednesday, October 21st. The company reported $6.99 earnings per share for the quarter, beating the consensus estimate of $4.71 by $2.28. Elevance Health had a return on equity of 14.97% and a net margin of 2.55%. The firm had revenue of $50.44 billion during the quarter, compared to the consensus estimate of $49.28 billion. During the same period in the previous year, the company posted $6.03 earnings per share. The firm’s quarterly revenue was up .7% on a year-over-year basis. As a group, research analysts forecast that Elevance Health, Inc. will post 29.15 earnings per share for the current year.
Elevance Health Dividend Announcement
The firm also recently announced a quarterly dividend, which will be paid on Friday, December 18th. Shareholders of record on Friday, December 4th will be given a dividend of $1.72 per share. The ex-dividend date of this dividend is Friday, December 4th. This represents a $6.88 dividend on an annualized basis and a yield of 1.7%. Elevance Health’s dividend payout ratio (DPR) is 29.34%.
Insider Activity
In other news, CFO Mark Kaye sold 10,584 shares of the stock in a transaction that occurred on Thursday, October 22nd. The shares were sold at an average price of $440.13, for a total transaction of $4,658,335.92. Following the transaction, the chief financial officer directly owned 19,919 shares in the company, valued at approximately $8,766,949.47. This trade represents a 34.70% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, EVP Ratnakar Lavu sold 1,300 shares of Elevance Health stock in a transaction that occurred on Thursday, November 5th. The shares were sold at an average price of $440.00, for a total transaction of $572,000.00. Following the transaction, the executive vice president directly owned 14,849 shares in the company, valued at approximately $6,533,560. The trade was a 8.05% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders own 0.34% of the company’s stock.
Hedge Funds Weigh In On Elevance Health
A number of large investors have recently bought and sold shares of the business. BlackRock Inc. purchased a new stake in Elevance Health during the second quarter worth $7,344,424,000. State Street Corp increased its holdings in shares of Elevance Health by 0.6% in the 3rd quarter. State Street Corp now owns 10,493,831 shares of the company’s stock valued at $4,080,211,000 after acquiring an additional 67,221 shares during the period. Wellington Management Group LLP increased its holdings in shares of Elevance Health by 12.0% in the 2nd quarter. Wellington Management Group LLP now owns 9,213,513 shares of the company’s stock valued at $3,563,142,000 after acquiring an additional 984,976 shares during the period. First Eagle Investment Management LLC increased its holdings in shares of Elevance Health by 1.4% in the 2nd quarter. First Eagle Investment Management LLC now owns 4,188,196 shares of the company’s stock valued at $1,619,701,000 after acquiring an additional 55,905 shares during the period. Finally, Bank of New York Mellon Corp bought a new position in shares of Elevance Health in the 2nd quarter worth $1,246,349,000. Institutional investors own 89.24% of the company’s stock.
Elevance Health Company Profile
Elevance Health, Inc. is a U.S. health benefits and services company. Formerly known as Anthem, Inc., it adopted the Elevance Health name in 2022 while retaining the Anthem brand for many of its health plans. The company offers medical, pharmacy, dental, vision and behavioral health coverage, including plans for individuals and employers as well as programs serving Medicare and Medicaid members. Its services also include care management, pharmacy benefit services and other health-related capabilities through its Carelon business.
Featured Articles
- Five stocks we like better than Elevance Health
- Drilling for Yield in the Gulf: Chevron Drops Anchor in Deepwater
- TJX Stock Flashes a Strong Bullish Signal as Its $3 Billion Buyback Plan Takes Shape
- Viking’s Low-Water Miss Looks Like a Buy-the-Dip Opportunity
- Why Amazon Wants the Chips and Blackstone Wants the Buildings
Receive News & Ratings for Elevance Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Elevance Health and related companies with MarketBeat.com's FREE daily email newsletter.
